These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25716386)

  • 1. Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.
    Najafi B; Ghaderi H; Jafari M; Najafi S; Ahmad Kiadaliri A
    Glob J Health Sci; 2014 Oct; 7(2):139-47. PubMed ID: 25716386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.
    Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A
    Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
    Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain].
    Rubio-Terrés C; Domínguez-Gil Hurlé A
    Rev Neurol; 2005 Jun 16-30; 40(12):705-10. PubMed ID: 15973634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA; Kamal KM; Pawar G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
    Abolfazli R; Hosseini A; Gholami Kh; Javadi MR; Torkamandi H; Emami S
    ISRN Neurol; 2012; 2012():786526. PubMed ID: 22928117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.
    Brown MG; Murray TJ; Sketris IS; Fisk JD; LeBlanc JC; Schwartz CE; Skedgel C
    Int J Technol Assess Health Care; 2000; 16(3):751-67. PubMed ID: 11028131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
    Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.
    Janković SM; Kostić M; Radosavljević M; Tesić D; Stefanović-Stoimenov N; Stevanović I; Raković S; Aleksić J; Folić M; Aleksić A; Mihajlović I; Biorac N; Borlja J; Vucković R
    Vojnosanit Pregl; 2009 Jul; 66(7):556-62. PubMed ID: 19678581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
    Zhang X; Hay JW; Niu X
    CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis.
    Visser LA; Folcher M; Delgado Simao C; Gutierrez Arechederra B; Escudero E; Uyl-de Groot CA; Redekop WK
    Pharmacoeconomics; 2022 Jan; 40(1):91-108. PubMed ID: 34480325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data.
    Meyer CM; Phipps R; Cooper D; Wright A
    J Manag Care Pharm; 2003; 9(2):168-74. PubMed ID: 14613346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests].
    Selmaj K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z
    Neurol Neurochir Pol; 2003; 37(6):1163-83. PubMed ID: 15174231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
    Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH
    Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.